AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...
The latest health news includes studies on medications for thyroid issues and breast cancer, the healthcare industry's ...
Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in England and Wales after negotiations collapsed over pricing. Jacqui Wise examines calls for NICE to ...
GlobalData on MSN3d
Adcendo raises $135m as ADC funding frenzy continuesFounded in 2017 as a spin-out from the University of Copenhagen and Rigshospitalet, Adcendo previously raised $102.8m (€98m) ...
Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...
At the Vaillant factory in Belper, in the English Peak District, engineers who were assembling gas boilers have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback